Amgen drug tied to death risks in tests as transfusion substitute

A new study of Amgen's Aranesp said it was linked to an almost 45% increase in death in trials testing it for reducing the need for blood transfusions in anemic cancer patients. Aranesp already is approved for treating the anemia itself, a side effect of chemotherapy, and an FDA advisory panel plans to meet in May to consider the entire class of erythropoiesis-stimulating agents.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA